Bioidentical hormone replacement therapy (BHRT) has recently emerged as a safer and low-risk alternative to conventional hormone replacement therapies, which are derived from horse-derived estrogens and other synthetic components. According to the FDA, very little evidence supports the safety of BHRT, so scientists conducted a study to examine the safety and risk factors associated with BHRT compared to conventional hormone therapies.

In their studies, scientists found that BHRT was associated with a lower risk for breast cancer and cardiovascular disease. Furthermore, patients experienced fewer adverse health effects with BHRT than with conventional therapies, of which synthetic components were a major risk factor. Until new scientific evidence proves otherwise, many experts in the health industry now recommend BHRT as the preferred treatment for hormone replacement therapy over other conventional therapies.

For more information, read the full article: Bioidentical hormone therapy associated with lower health risks than conventional hormone therapies